Dapagliflozin in patients with critical illness: rationale and design of the DEFENDER study.

ABSTRACT:

Background

Critical illness is a major ongoing health care burden worldwide and is associated with high mortality rates. Sodium-glucose cotransporter-2 inhibitors have consistently shown benefits in cardiovascular and renal outcomes. The effects of sodium-glucose cotransporter-2 inhibitors in acute illness have not been properly investigated.

Methods

DEFENDER is an investigator-initiated, multicenter, randomized, open-label trial designed to evaluate the efficacy and safety of dapagliflozin in 500 adult participants with acute organ dysfunction who are hospitalized in the intensive care unit. Eligible participants will be randomized 1:1 to receive dapagliflozin 10mg plus standard of care for up to 14 days or standard of care alone. The primary outcome is a hierarchical compo

SUBMITTER: Tavares CAM 

PROVIDER: S-EPMC10734800 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature